S0173 is a Rhode Island health and human services bill focused on prescription drug cost containment, especially within the Medicaid program. Its stated purpose is to protect Rhode Islanders and the state Medicaid program from high drug costs by increasing pharmacy benefit manager (PBM) transparency and accountability. The bill amends the duties of the secretary of the Executive Office of Health and Human Services (EOHHS) to add explicit oversight of managed care organizations and PBMs, with a particular emphasis on preventing practices that raise costs without improving care.
The bill directs EOHHS to ensure that Medicaid contractors and PBMs are transparent, do not increase unnecessary costs, and improve patient outcomes. Most notably, it requires contracts with managed care organizations to prohibit PBM spread pricing, a pricing model in which a PBM charges a health plan more than it reimburses the pharmacy and keeps the difference. The bill also reinforces the secretary’s broader authority over Medicaid coordination, reporting, budget integration, data management, and program integrity, while preserving existing EOHHS responsibilities related to health and human services administration.
More broadly, the bill expands and restates the secretary’s oversight duties across Medicaid and other health and human services functions, including review of Medicaid waivers and state plan changes, annual reporting on Medicaid expenditures and outcomes, coordination with HealthSource RI, and efforts to improve efficiency, accountability, and service delivery. It also references opportunities to reduce fixed eligibility thresholds through sliding-scale benefit reductions up to 450% of the federal poverty level, though the bill’s central operative change is the PBM transparency and anti-spread-pricing requirement.
The bill’s impact on state law is to strengthen EOHHS authority over Medicaid contracting and to codify a prohibition on PBM spread pricing in Medicaid-related arrangements. It affects the executive office, Medicaid managed care organizations, pharmacy benefit managers, pharmacies, and Medicaid beneficiaries by potentially changing how prescription drug reimbursements are structured and how costs are passed through to the state and patients. In practical terms, it is intended to reduce Medicaid spending pressure and improve oversight of drug pricing practices.
The available voting history suggests strong bipartisan or at least broad legislative support, with the bill passing 34-0 on May 6, 2025. No committee transcript excerpts were provided, and no recorded opposition appears in the supplied materials. Based on the text and vote, the overall sentiment appears favorable, with the bill framed as a consumer- and taxpayer-protection measure aimed at lowering drug costs and improving accountability. No specific points of contention are documented in the provided record, though the PBM industry and managed care contracting practices are the most likely areas where implementation concerns could arise.
The bill amends Rhode Island General Laws § 42-7.2-5 to expand the EOHHS secretary’s duties, specifically authorizing oversight of Medicaid contracting practices and requiring action to prevent PBM spread pricing in Medicaid-related contracts. It affects state Medicaid administration, managed care organizations, PBMs, and related health and human services reporting and budgeting functions, while reinforcing existing authority over program coordination, data, and accountability.
The bill appears to have been received positively, with unanimous passage in the Senate (34-0) and no committee discussion or recorded opposition in the provided materials. The framing of the bill as a cost-control and transparency measure suggests broad support for limiting prescription drug costs and strengthening Medicaid oversight.
No explicit contention is documented in the provided record. The main policy issue embedded in the bill is the prohibition on PBM spread pricing and the broader expansion of EOHHS oversight, which could draw concern from PBMs, managed care organizations, or contractors affected by tighter pricing and reporting requirements. However, the supplied materials do not show any formal opposition or disputed amendments.